Xtant Medical Swings to Profit on Surging License Revenue, Cuts Costs

TL;DR

**XTNT is finally turning the corner with a profit, driven by smart licensing deals and tighter cost controls – time to watch this one closely!**

AI Summary

Xtant Medical Holdings, Inc. reported a significant turnaround for the nine months ended September 30, 2025, achieving a net income of $4.916 million, a substantial improvement from a net loss of $13.284 million in the prior year period. Total revenue increased by 18.44% to $101.570 million, up from $85.754 million, primarily driven by a new license revenue stream of $14.078 million, which was non-existent in 2024. Product revenue remained relatively stable, decreasing slightly by 0.59% to $27.772 million for the three months ended September 30, 2025, compared to $27.937 million in the same period of 2024. Gross profit surged by 27.45% to $66.519 million for the nine-month period, reflecting improved operational efficiency and the impact of license revenue. Operating expenses decreased by 6.56% to $58.291 million, contributing to the positive income from operations of $8.228 million, a stark contrast to the $10.192 million operating loss in the prior year. The company also saw an increase in cash and cash equivalents to $10.400 million as of September 30, 2025, from $6.199 million at December 31, 2024, partly due to $5.000 million in advances from the pending sale of Coflex/CoFix assets.

Why It Matters

This turnaround is critical for Xtant Medical, signaling a potential shift towards sustainable profitability after years of losses. The new license revenue stream, contributing $14.078 million, demonstrates successful monetization of intellectual property, which could provide a more stable and higher-margin revenue source. For investors, this indicates improved financial health and a stronger competitive position in the medical device market, especially as the company aims to control its supply chain and become a more diverse biologics producer. Employees and customers could benefit from a more stable company, while the broader market will watch if Xtant can maintain this momentum and further reduce its reliance on third-party manufacturing, potentially impacting competitors in the orthopedic and biologics space.

Risk Assessment

Risk Level: medium — While Xtant Medical achieved net income, product revenue for the quarter decreased slightly, indicating potential challenges in core sales growth. The company also carries significant long-term debt of $17.404 million and a line of credit balance of $11.308 million, which could pose liquidity risks if profitability doesn't sustain. Furthermore, the pending sale of Coflex/CoFix assets, while providing a $5.000 million advance, introduces uncertainty regarding future revenue streams from those products.

Analyst Insight

Investors should monitor Xtant Medical's ability to sustain its license revenue and grow core product sales in future quarters. Evaluate the impact of the Coflex/CoFix asset sale on long-term strategy and revenue. Consider the company's debt management and cash flow generation as key indicators for continued financial health.

Financial Highlights

debt To Equity

N/A

revenue

$101.570M

operating Margin

8.10%

total Assets

N/A

total Debt

N/A

net Income

$4.916M

eps

N/A

gross Margin

65.50%

cash Position

$10.400M

revenue Growth

+18.44%

Revenue Breakdown

Key Numbers

• $4.916M — Net Income (Nine months ended Sept 30, 2025, compared to -$13.284M loss in prior year.)
• $101.570M — Total Revenue (Nine months ended Sept 30, 2025, an 18.44% increase from $85.754M.)
• $14.078M — License Revenue (New revenue stream for nine months ended Sept 30, 2025, zero in prior year.)
• $27.772M — Product Revenue (Three months ended Sept 30, 2025, a slight decrease from $27.937M.)
• $66.519M — Gross Profit (Nine months ended Sept 30, 2025, a 27.45% increase from $52.192M.)
• $58.291M — Total Operating Expenses (Nine months ended Sept 30, 2025, a 6.56% decrease from $62.384M.)
• $8.228M — Income from Operations (Nine months ended Sept 30, 2025, a significant improvement from -$10.192M loss.)
• $10.400M — Cash and Cash Equivalents (As of Sept 30, 2025, up from $6.199M at Dec 31, 2024.)
• $5.000M — Advances from Asset Sale (Received from pending sale of Coflex/CoFix assets.)
• 140,004,240 — Common Shares Outstanding (As of November 7, 2025.)

Key Players & Entities

• Xtant Medical Holdings, Inc. (company) — registrant
• Companion Spine, LLC (company) — purchaser of Coflex and CoFix assets
• Nantahala Capital Management, LLC (company) — significant common stock owner
• NYSE American LLC (regulator) — exchange where common stock is registered
• $10.400 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $4.916 million (dollar_amount) — net income for the nine months ended September 30, 2025
• $14.078 million (dollar_amount) — license revenue for the nine months ended September 30, 2025
• $101.570 million (dollar_amount) — total revenue for the nine months ended September 30, 2025
• $5.000 million (dollar_amount) — advances from pending sale of Coflex/CoFix assets
• $17.404 million (dollar_amount) — long-term debt as of September 30, 2025

FAQ

Risk Factors

• Dependence on Key Products [medium — financial]: The company's product revenue remained relatively stable, decreasing slightly by 0.59% for the three months ended September 30, 2025. This indicates a potential over-reliance on existing product lines and a need for continued innovation or market penetration to drive growth.
• Impact of New Revenue Streams [medium — financial]: The significant increase in net income is largely attributable to a new license revenue stream of $14.078 million. The sustainability and future growth of this new stream are critical for continued financial performance.
• Integration of New Revenue [low — operational]: While license revenue boosted overall revenue and profitability, the operational integration and management of this new stream require careful attention to ensure it complements the existing business without creating undue complexity or distraction.
• Cash Position and Asset Sale [medium — financial]: The increase in cash to $10.400 million as of September 30, 2025, is partly due to $5.000 million in advances from the pending sale of Coflex/CoFix assets. The completion and terms of this sale are important for future liquidity.

Industry Context

Xtant Medical Holdings operates in the global medical technology sector, specifically focusing on orthobiologics and spinal implant fixation systems. The industry is characterized by innovation in surgical techniques and materials aimed at improving patient outcomes in complex spine procedures. Competition likely comes from larger, established medical device companies as well as specialized orthobiologics firms.

Regulatory Implications

As a medical technology company, Xtant is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance are critical. Any changes in regulatory requirements or failure to maintain compliance could significantly impact product development, market access, and financial performance.

What Investors Should Do

1. Monitor the sustainability of license revenue.
2. Evaluate the impact of the Coflex/CoFix asset sale.
3. Analyze product revenue trends.

Key Dates

• 2025-09-30: End of Nine-Month Period — Reported significant net income of $4.916 million and total revenue of $101.570 million, marking a substantial turnaround from the prior year.
• 2025-09-30: Quarter End — Product revenue for the three months ended this date was $27.772 million, a slight decrease from the prior year, while cash and cash equivalents stood at $10.400 million.
• 2024-12-31: Prior Year End — Cash and cash equivalents were $6.199 million, providing a baseline for the increase observed by September 30, 2025.

Glossary

Orthobiologics

Biologic materials used in orthopedic surgery to promote healing and bone regeneration. (Xtant Medical Holdings focuses on the design, development, and commercialization of these products for spinal fusion procedures.)

Spinal Fusion

A surgical procedure to permanently connect two or more vertebrae in the spine. (Xtant's portfolio of orthobiologics and spinal implant fixation systems are designed to facilitate this procedure.)

GAAP

Generally Accepted Accounting Principles, the common set of accounting principles, standards, and procedures by which financial statements are prepared in the United States. (The company's financial statements are prepared in accordance with GAAP.)

Forward-looking statements

Statements about future events or conditions that are based on current expectations and projections, subject to risks and uncertainties. (The 10-Q filing contains such statements, which investors should consider with caution due to inherent risks.)

Year-Over-Year Comparison

Compared to the prior year period, Xtant Medical Holdings has demonstrated a significant financial turnaround. Total revenue for the nine months ended September 30, 2025, increased by 18.44% to $101.570 million, largely due to a new $14.078 million license revenue stream. Gross profit surged by 27.45%, and operating expenses decreased by 6.56%, leading to a positive income from operations of $8.228 million, a substantial improvement from a $10.192 million operating loss. This shift resulted in a net income of $4.916 million, compared to a net loss of $13.284 million in the prior year.

Key Financial Figures

• $0.000001 — ch registered Common stock, par value $0.000001 per share XTNT NYSE American LLC

Filing Documents

• form10-q.htm (10-Q) — 1238KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-25-021512.txt ( ) — 6290KB
• xtnt-20250930.xsd (EX-101.SCH) — 40KB
• xtnt-20250930_cal.xml (EX-101.CAL) — 71KB
• xtnt-20250930_def.xml (EX-101.DEF) — 159KB
• xtnt-20250930_lab.xml (EX-101.LAB) — 376KB
• xtnt-20250930_pre.xml (EX-101.PRE) — 306KB
• form10-q_htm.xml (XML) — 1008KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 1 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 27 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 27 PART II. OTHER INFORMATION 28 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 28 ITEM 1A.

RISK FACTORS

RISK FACTORS 28 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 29 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 29 ITEM 4. MINE SAFETY DISCLOSURES 29 ITEM 5. OTHER INFORMATION 30 ITEM 6. EXHIBITS 30 This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see "Cautionary Statement Regarding Forward-Looking Statements." As used in this report, unless the context indicates another meaning, the terms "we," "us," "our," "Xtant," "Xtant Medical," and the "Company" mean Xtant Medical Holdings, Inc. and its wholly owned subsidiaries, all of which are consolidated on Xtant's condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the and symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. We include our website address throughout this report for reference only. The information contained on or connected to our website is not incorporated by reference into this report. i CAUTIONARY The of the Private Securities Litigation Reform A

Business

Business Description and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. ("Xtant"), a Delaware corporation, and its wholly owned subsidiaries, which are jointly referred to herein as "Xtant" or the "Company". The terms "we," "us" and "our" also refer to Xtant. All intercompany balances and transactions have been eliminated in consolidation. Xtant is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The accompanying condensed consolidated balance sheet as of December 31, 2024, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2025. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto, which are included in Xtant's Annual Report on Form 10-K for the year ended December 31, 2024. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation. Use of Estimates

View Full Filing

View this 10-Q filing on SEC EDGAR